US2009012269A1PendingUtilityA1

Humanized anti-ccr2 antibodies and methods of use therefor

65
Assignee: MILLENNIUM PHARM INCPriority: Oct 19, 2001Filed: Jun 30, 2008Published: Jan 8, 2009
Est. expiryOct 19, 2021(expired)· nominal 20-yr term from priority
A61P 9/10C07H 21/04A61P 19/00C07K 2317/24C07K 16/00A61P 11/00C07K 16/2866A61P 19/02C07K 2319/00
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Claims

exact text as granted — not AI-modified
1 . A humanized immunoglobulin heavy chain, or antigen binding fragment thereof, having binding specificity for CCR2 and comprising the amino acid sequence of SEQ ID NO:17 and the amino acid sequence of SEQ ID NO: 110 or a portion thereof. 
     
     
         2 . The humanized immunoglobulin heavy chain or antigen binding fragment thereof of  claim 1 , having a variable region and a constant region, wherein the variable region is encoded by the nucleic acid sequence of SEQ ID NO:108. 
     
     
         3 . The humanized immunoglobulin heavy chain or antigen binding fragment thereof of  claim 1 , having a variable region and a constant region, wherein the constant region is encoded by the nucleic acid sequence of SEQ ID NO:111 or a portion thereof. 
     
     
         4 . The humanized immunoglobulin heavy chain or antigen binding fragment thereof of  claim 1 , having a variable and a constant region, wherein the variable region is encoded by the nucleic acid sequence of SEQ ID NO:108 and the constant region is encoded by the nucleic acid sequence of SEQ ID NO:111 or a portion thereof. 
     
     
         5 . A humanized immunoglobulin light chain, or antigen binding fragment thereof, having binding specificity for CCR2 and comprising the amino acid sequence of SEQ ID NO:12 and the amino acid sequence of SEQ ID NO: 112. 
     
     
         6 . The humanized immunoglobulin light chain or antigen binding fragment thereof of  claim 5 , having a variable region and a constant region, wherein the variable region is encoded by the nucleic acid sequence of SEQ ID NO:109. 
     
     
         7 . The humanized immunoglobulin light chain or antigen binding fragment thereof of  claim 5 , having a variable region and a constant region, wherein the constant region is encoded by the nucleic acid sequence of SEQ ID NO:113 or a portion thereof. 
     
     
         8 . The humanized immunoglobulin light chain or antigen binding fragment thereof of  claim 5 , having a variable and a constant region, wherein the variable region is encoded by the nucleic acid sequence of SEQ ID NO:109 and the constant region is encoded by the nucleic acid sequence of SEQ ID NO:113 or a portion thereof. 
     
     
         9 . A humanized immunoglobulin or antigen binding portion thereof having binding specificity for CCR2 and having a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO:17 and an amino acid sequence of SEQ ID NO:110 or a portion thereof, and the light chain comprises an amino acid sequence of SEQ ID NO:12. 
     
     
         10 . The humanized immunoglobulin or antigen binding fragment thereof of  claim 9 , wherein the light chain further comprises the amino acid sequence of SEQ ID NO:112. 
     
     
         11 . The humanized immunoglobulin or antigen binding fragment thereof of  claim 10 , wherein the humanized immunoglobulin comprises two heavy chains and two light chains.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.